D James B St John
Overview
Explore the profile of D James B St John including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feletto E, Yu X, Lew J, St John D, Jenkins M, Macrae F, et al.
Cancer Epidemiol Biomarkers Prev
. 2018 Dec;
28(1):83-90.
PMID: 30530848
Background: Colorectal cancer is the third most commonly diagnosed cancer in Australia. Emerging evidence from several countries suggests increasing incidence in people aged <50 years. Methods: We assessed colon and...
2.
Jenkins M, Ait Ouakrim D, Boussioutas A, Hopper J, Ee H, Emery J, et al.
Med J Aust
. 2018 Oct;
209(10):455-460.
PMID: 30359558
Screening is an effective means for colorectal cancer prevention and early detection. Family history is strongly associated with colorectal cancer risk. We describe the rationale, evidence and recommendations for colorectal...
3.
Lew J, St John D, Macrae F, Emery J, Ee H, Jenkins M, et al.
Cancer Epidemiol Biomarkers Prev
. 2018 Sep;
27(12):1450-1461.
PMID: 30190276
Background: The Australian National Bowel Cancer Screening Program (NBCSP) is rolling out 2-yearly immunochemical fecal occult blood test screening in people aged 50 to 74 years. This study aimed to...
4.
Lew J, St John D, Macrae F, Emery J, Ee H, Jenkins M, et al.
Int J Cancer
. 2018 Feb;
143(2):269-282.
PMID: 29441568
The Australian National Bowel Cancer Screening Program (NBCSP) will fully roll-out 2-yearly screening using the immunochemical Faecal Occult Blood Testing (iFOBT) in people aged 50 to 74 years by 2020....
5.
Lew J, St John D, Xu X, Greuter M, Caruana M, Cenin D, et al.
Lancet Public Health
. 2017 Dec;
2(7):e331-e340.
PMID: 29253458
Background: No assessment of the National Bowel Screening Program (NBCSP) in Australia, which considers all downstream benefits, costs, and harms, has been done. We aimed to use a comprehensive natural...
6.
7.
Cenin D, St John D, Ledger M, Slevin T, Lansdorp-Vogelaar I
Med J Aust
. 2014 Oct;
201(8):456-61.
PMID: 25332032
Objectives: To estimate the impact of various expansion scenarios of the National Bowel Cancer Screening Program (NBCSP) on the number of bowel cancer deaths prevented; and to investigate the impact...
8.
Pignone M, Flitcroft K, Howard K, Trevena L, Salkeld G, St John D
Med J Aust
. 2011 Mar;
194(4):180-5.
PMID: 21401458
Objective: To examine the costs and cost-effectiveness of full implementation of biennial bowel cancer screening for Australian residents aged 50-74 years. Design And Setting: Identification of existing economic models from...
9.
van Vliet C, Dowty J, van Vliet J, Smith L, Mead L, Macrae F, et al.
Hum Mutat
. 2010 Dec;
32(2):207-12.
PMID: 21120946
Genetic diseases associated with dynamic mutations in microsatellite DNA often display parent-of-origin effects (POEs) in which the risk of disease depends on the sex of the parent from whom the...
10.
Mead L, Jenkins M, Young J, Royce S, Smith L, St John D, et al.
Clin Cancer Res
. 2007 May;
13(10):2865-9.
PMID: 17504984
Purpose: Microsatellite instability (MSI) testing of colorectal cancer tumors is used as a screening tool to identify patients most likely to be mismatch repair (MMR) gene mutation carriers. We wanted...